1,584 Matching Annotations
  1. Feb 2022
  2. Jan 2022
    1. Tom Wenseleers. (2022, January 30). Seems that the second Omicron subvariant BA.2 may soon be about to cause cases to start rising again in South Africa... Or at least to stop the decline in new infections. Shows how fast immunity wanes & evolution can catch up. Https://t.co/3y4xqPgZ0L [Tweet]. @TWenseleers. https://twitter.com/TWenseleers/status/1487919837670219781

    1. Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Manning, K. E., Edara, V.-V., Lai, L., Ellis, M., Moore, K. M., Floyd, K., Foster, S. L., Posavad, C. M., … Montefiori, D. C. (2022). SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2119912

    1. Elliott, P., Eales, O., Bodinier, B., Tang, D., Wang, H., Jonnerby, J., Haw, D., Elliott, J., Whitaker, M., Walters, C., Atchison, C., Diggle, P., Page, A., Trotter, A., Ashby, D., Barclay, W., Taylor, G., Ward, H., Darzi, A., … Donnelly, C. (2022). Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 [Working Paper]. http://spiral.imperial.ac.uk/handle/10044/1/93887

    1. Tom Peacock. (2022, January 3). Lots of chat about B.1.640.2 in the last few days—Just a few points to keep in mind: - B.1.640.2 actually predates Omicron—In all that time there are exactly... 20 sequences (compared to the >120k Omis in less time) Def not one worth worrying about too much at the mo... [Tweet]. @PeacockFlu. https://twitter.com/PeacockFlu/status/1478118173903839237

    1. Helen Branswell. (2022, January 11). 1. #Omicron’s takeover was stunningly rapid and is now nearly complete, at least in the U.S. The latest “Nowcast” from @CDCgov (which uses recent data to model what’s happen now) suggests most of what is circulating here now is omicron. Https://t.co/6w3e8Ut5NW [Tweet]. @HelenBranswell. https://twitter.com/HelenBranswell/status/1480970453313277954

    1. Home

      Zuo, F., Abolhassani, H., Du, L., Piralla, A., Bertoglio, F., Campos-Mata, L. de, Wan, H., Schubert, M., Wang, Y., Sun, R., Cassaniti, I., Vlachiotis, S., Kumagai-Braesch, M., Andréll, J., Zhang, Z., Xue, Y., Wenzel, E. V., Calzolai, L., Varani, L., … Pan-Hammarström, Q. (2022). Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant (p. 2022.01.04.22268755). https://doi.org/10.1101/2022.01.04.22268755

    1. Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A., Kawabata, H., Sominsky, L., Clark, J., Adelsberg, D. C., Bielak, D., Gonzalez-Reiche, A. S., Dambrauskas, N., Vigdorovich, V., Group, P. S., Srivastava, K., Sather, D. N., Sordillo, E. M., Bajic, G., van Bakel, H., … Krammer, F. (2021). Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. https://doi.org/10.1038/d41586-021-03846-z

    1. Keeling, M. J., Brooks-Pollock, E., Challen, R. J., Danon, L., Dyson, L., Gog, J. R., Guzman-Rincon, L., Hill, E. M., Pellis, L. M., Read, J. M., & Tildesley, M. (2021). Short-term Projections based on Early Omicron Variant Dynamics in England. (p. 2021.12.30.21268307). https://doi.org/10.1101/2021.12.30.21268307

  3. Dec 2021
    1. Genome sequencing is complex, and only 38 laboratories across the country (https://bit.ly/3ED4vrP) have the ability to sequence a virus which is as infectious as this

      Viral Genome sequencing facility in India

      • 38 labs
    1. A Marm Kilpatrick. (2021, November 24). How do we get broad immunity to SARS-CoV-2 that will protect against future variants? 2 studies (are there more?) suggest that vaccination followed by infection gives broader protection than infection followed by vaccination. @florian_krammer @profshanecrotty @GuptaR_lab https://t.co/rqdf6rE9ej [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1463391782742335491

    1. Colin Davis. (2021, December 20). Update for 20th Dec. The trend line still reflects 1.8 day doubling (it’s 1.7 days if we look at just the last week). Today’s number is down, but I wouldn’t read too much into that at this point. Https://t.co/kOCjxhRbop [Tweet]. @ProfColinDavis. https://twitter.com/ProfColinDavis/status/1472969632705392640

    1. Arieh Kovler. (2021, November 26). Israel has identified four cases of the B.1.1.529 variant, all recent travellers. One case, a 32-year-old woman returning from South Africa, was triple vaccinated with Pfizer and had her 3rd dose just two months ago. [Tweet]. @ariehkovler. https://twitter.com/ariehkovler/status/1464190991204859919

    1. Tom Moultrie. (2021, December 17). A 1-figure Gauteng update, bringing in data through Wednesday 15/12 (PCR only; by date of collection). The turn continues. On similar metrics (not shown) ALL northern provinces (NW, GT, MP, LP) seem to have now turned. Https://t.co/6Bh3kZsooK [Tweet]. @tomtom_m. https://twitter.com/tomtom_m/status/1471723711287996416

    1. Jay Varma. (2021, December 16). Um, we’ve never seen this before in #NYC. Test positivity doubling in three days 12/9—3.9% 12/10—4.2% 12/11—6.4% 12/12—7.8% Note: Test % is only for PCR & NYC does more per capita daily than most places ~67K PCR/day + 19K [reported] antigen over past few days (1/2) https://t.co/PhxsZq55jn [Tweet]. @DrJayVarma. https://twitter.com/DrJayVarma/status/1471485885447389186

    1. Garcia-Beltran, W. F., Denis, K. J. S., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., Feldman, J., Gregory, D. J., Poznansky, M. C., Schmidt, A. G., Iafrate, A. J., Naranbhai, V., & Balazs, A. B. (2021). MRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (p. 2021.12.14.21267755). https://doi.org/10.1101/2021.12.14.21267755

    1. Dr Duncan Robertson. (2021, December 15). Cases on the dashboard exclude reinfections.And there are a lot of reinfections as far as Omicron is concerned h/t @AlistairHaimes and @Peston And this is only cases reported today—Not from infections today With a 2-day doubling time for Omicron, this isn’t great https://t.co/fU2RLhshtn [Tweet]. @Dr_D_Robertson. https://twitter.com/Dr_D_Robertson/status/1471156538681315336

    1. Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., Anton, L., Weber, L. M., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Hörber, S., Peter, A., Meisner, C., … Walz, J. S. (2021). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04232-5

    1. Sean Phelan. (2021, November 26). Striking how some media coverage is assuming (without caveats) that the Belgian case brought the new variant “from” Egypt or Turkey.There’s no chance they picked it up after returning to Belgium of course. How could that happen..we only have a 7-day average of 17,000 cases a day [Tweet]. @seanphelan8. https://twitter.com/seanphelan8/status/1464252432033136659

    1. Seth Trueger. (2021, June 26). friendly reminder that “more transmissible” is by itself REALLY BAD for a pandemic. Even small increases in R₀ mean more potential for spread, more cases, more deaths etc please get your vax & help others get theirs https://t.co/mlojYmp71j [Tweet]. @MDaware. https://twitter.com/MDaware/status/1408811800108355586

    1. Eric Feigl-Ding. (2021, December 2). A rise in possible #Omicron in England—Tripling (0.1 to 0.3) of S-Gene dropout PCR signal, which is a proxy for Omicron (before 🧬 sequencing confirms). @_nickdavies estimates this represents around ~60 cases in 🏴󠁧󠁢󠁥󠁮󠁧󠁿. Still early—But it displacing #DeltaVariant is not good sign. 🧵 https://t.co/4aIiqiVsqH [Tweet]. @DrEricDing. https://twitter.com/DrEricDing/status/1466234026843205637

    1. nference. (2021, November 27). Here is how B.1.1.529 (#Omicron #B11529) compares to Alpha, Beta, Gamma, Delta variants. Omicron has highest novel Spike mutations including striking cluster on the “crown” suggesting significant selection pressure & antigenic distinction from prior strains (Credits: Nference) https://t.co/4oZQbjhbG8 [Tweet]. @_nference. https://twitter.com/_nference/status/1464404770098229250

    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  4. Nov 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

    1. Stephen Reicher. (2021, November 26). 55.1% of the worlds population has had one dose of Covid vaccine. 29% in South Africa 10.1% in Africa as a whole Only 6% of Africans are fully vaccinated So is it any surprise new variants are arising from Africa? What doesn’t go around (as vaccine) Comes around (as Covid). Https://t.co/0X0vZ6flmc [Tweet]. @ReicherStephen. https://twitter.com/ReicherStephen/status/1464202267196858380

    1. Prof. Christina Pagel. (2021, November 24). Meanwhile AY.4.2 (Delta grandchild) continues its very slow path to English dominance. Makes life a bit harder by being a bit more transmissible but luckily doesn’t seem any worse than Delta in any other respect. Https://t.co/kB0V0Z66GT [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1463508172941967365

    1. Jeffrey Barrett. (2021, October 19). Proportion of AY.4.2 (now on http://covid19.sanger.ac.uk) has been steadily increasing in England, which is a pattern that is quite different from other AY lineages. Several of them rose when there was still Alpha to displace, but none has had a consistent advantage vs other Delta. Https://t.co/mD5gQzKxgV [Tweet]. @jcbarret. https://twitter.com/jcbarret/status/1450408485829718039

    1. Prof. Christina Pagel. (2021, November 3). Good @NatGeo article by @Ecquis on the growing AY.4.2 variant in the UK with lots of great experts explaining it. And a little bit of me too! At its current growth rate, it will probably become dominant in UK by the end of the year. Https://t.co/X9O9kbew2L [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1455899379475361795

    1. Dhar, M. S., Marwal, R., VS, R., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., Mishra, S., Whittaker, C., Fatihi, S., Datta, M., Singh, P., Sharma, U., Ujjainiya, R., Bhatheja, N., Divakar, M. K., … Rakshit, P. (n.d.). Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science, 0(0), eabj9932. https://doi.org/10.1126/science.abj9932

  5. Oct 2021
    1. Singanayagam, A., Hakki, S., Dunning, J., Madon, K. J., Crone, M. A., Koycheva, A., Derqui-Fernandez, N., Barnett, J. L., Whitfield, M. G., Varro, R., Charlett, A., Kundu, R., Fenn, J., Cutajar, J., Quinn, V., Conibear, E., Barclay, W., Freemont, P. S., Taylor, G. P., … Lackenby, A. (2021). Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00648-4

    1. Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., … Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 6197. https://doi.org/10.1038/s41467-021-26499-y

    1. Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., Giglioli, G., De Santi, C., Fabbiani, M., Rancan, I., Tumbarello, M., Montagnani, F., Sala, C., Montomoli, E., & Rappuoli, R. (2021). Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 1–7. https://doi.org/10.1038/s41586-021-04117-7

    1. Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. The Lancet, 398(10309), 1407–1416. https://doi.org/10.1016/S0140-6736(21)02183-8

    1. Siddle, K. J., Krasilnikova, L. A., Moreno, G. K., Schaffner, S. F., Vostok, J., Fitzgerald, N. A., Lemieux, J. E., Barkas, N., Loreth, C., Specht, I., Tomkins-Tinch, C. H., Silbert, J., Schaeffer, B., Taylor, B. P., Loftness, B., Johnson, H., Schubert, P. L., Shephard, H. M., Doucette, M., … Sabeti, P. C. (2021). Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts (p. 2021.10.20.21265137). https://doi.org/10.1101/2021.10.20.21265137

    1. Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., … Gupta, R. K. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 1–6. https://doi.org/10.1038/s41586-021-03944-y

    1. Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-021-01449-9

  6. Sep 2021